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Background: An essential medicine (EM) system has been implemented in China to reduce patients’ financial
burden and to make the use of drugs more rational. This study aims to evaluate the current state of the EM system
in Guangdong Province.
Methods: We conducted surveys in 21 cities in 2012, covering 98 medical institutions, 1,509 doctors, 17 medicine
manufacturers, and 17 distribution companies. We also reviewed outpatient prescriptions (n = 9,941) for treating
hypertension, diabetes, bacterial infections and gout to measure the rational use of drugs in secondary and tertiary
(upper-level) hospitals.
Results: The percentage of non-priority EM use ranged from 8.1% to 10.7% in upper-level hospitals, and this
non-priority use significantly increased prescription drug costs. Other types of inappropriate medicine use were
found more frequently in treating bacterial infections (7.4%) than in treating hypertension (1.6%), diabetes (1.3%)
and gout (1.7%). Tertiary hospitals prescribed fewer EMs than secondary hospitals; moreover, tertiary hospitals had
higher prescription drug costs. The zero mark-up policy decreased prescription drug costs in secondary hospitals.
The survey revealed that forced full-prescription EM use might lead to fewer patient visits to primary hospitals.
Manufacturers had halted the production of four (1, 23) types of EMs at the time of the survey.
Conclusions: Encouraging the priority use of EMs and implementation of the zero mark-up policy were effective in
curtailing prescription medicine costs in upper-level hospitals. Further work should focus on the following: creating
guidelines to enhance rational prescription behavior, establishing policies to support EM use in upper-level hospitals
and improving the bidding system to ensure a steady supply of the lowest-priced generic drugs.
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Health care expenditures per capita have risen dramatic-
ally in China – from US$ 21 to US$ 220 between 1995
and 2010 [1]. As a result of this rapid rise in health care
expenditures, more and more Chinese citizens are com-
plaining about the high cost of medical care and the in-
equitable distribution of medical resources. Health care
reform was launched in 2009 to achieve universal health
care coverage and reduce the financial burden on pa-
tients [2]. The details of this reform include building a* Correspondence: zsyylcyx@163.com
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unless otherwise stated.national list of essential medicines (EMs), centralizing
medical procurement and provincial-level tender, and
providing EMs at cost in primary hospitals (the zero
mark-up policy). This reform also set clinical standards
aimed at eradicating irrational prescription behavior [3],
such as doctors overprescribing drugs to receive kick-
backs from pharmaceutical salesmen. The study showed
that implementing an EM system was effective in shift-
ing prescribing indicators toward the standard values
recommended by the WHO [4].
The health care reform affects the interests of the en-
tire chain of medical services. Many health care pro-
viders have complained about higher workloads and
lower incomes since the reform [5]. Additionally, someThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pensate for the losses caused by the reform and when
government subsidies are insufficient [6]. Primary hospi-
tals are asked to prescribe only EMs and to adopt the
zero mark-up policy. The current reform focuses on pri-
mary hospitals, and many papers have reported the ef-
fects of the reform on practices at primary hospitals in
remote areas [7-9] and in individual cities [10-12]. Mean-
while, secondary and tertiary (upper-level) hospitals are
asked to prescribe EMs as a priority and encouraged to
pilot the zero mark-up policy. Although these upper-level
hospitals treat the majority of patients in China, insuffi-
cient attention has been paid to them since the reform.
In the present study, we reviewed prescriptions (n =
9,941) in upper-level hospitals for treating hypertension,
diabetes, bacterial infections and gout. Furthermore, we
integrated surveys of different levels of hospitals and
doctors, pharmaceutical manufacturers and distribution
companies to systematically evaluate the current state of
the EM system in one of China’s most developed prov-
inces (Guangdong).
Methods
Guangdong Province is located in southern China; it in-
cludes 21 cities and has a population of 104.3 million.
Guangdong is the largest province in China as measured
by GDP, which reached approximately $904.05 billion in
2012. This study used the “2009 National Essential Med-
icines List,” which contained 307 generic drugs, and the
“Guangdong Provincial Supplementary Essential Medi-
cines List,” which included another 244 essential drugs.
We intended to enroll one secondary, one tertiary and
four primary hospitals in each city to participate in the
study. Ultimately, 35 upper-level and 63 primary hospi-
tals participated in the survey, and 29 upper-level hospi-
tals participated in the prescription analysis.
Semi-structured questionnaires were designed for this
study based on a literature review and a consultation with
a health care specialist and were approved by the provin-
cial and local health bureaus. A regional director was set
in each city to ensure the study’s quality, and each director
was an experienced clinical pharmacist. The directors
were responsible for the survey and data monitoring.
This study was approved by the ethics committees at
Zhongshan Hospital of Sun Yat-sen University. Partici-
pants could not be identified from the recorded data, and
all participants gave their informed consent. The final re-
sults would be submitted to the provincial health bureaus.
The study included two parts: a cross-sectional analysis of
prescription and semi-structured surveys.
Prescription analysis
Outpatient prescriptions were analyzed in each hospital in
June 2012 under the following official sets of guidelines:“Practices of hospital prescription review”, “Guiding prin-
ciples of the clinical use of antibiotics”, and “Guiding prin-
ciples of prescription review in Guangdong Province”.
Prescriptions for treating hypertension, diabetes, bacterial
infections and gout were selected. This analysis sought to
characterize the overall rate of prescribing EMs and the
rate of inappropriate prescribing practices. In each facility,
100 prescriptions for each disease were systematically se-
lected by their clinical pharmacist and regional director
using an arithmetic method. If fewer than 100 prescrip-
tions were issued, then all prescriptions were included; if
there was any discrepancy with respect to whether a pre-
scription constituted an irrational prescription, then a
consensus was reached by discussion. The number of total
drugs, the number of EMs, the cost of all drugs, the cost
of the EMs, and the inappropriate use of medicines were
recorded for this study. The data were subjected to strati-
fied analysis based on the hospital type, the rational use of
medicines and whether the zero mark-up policy was
adopted.Surveys of health care facilities, manufacturers and
distribution companies
In each health care facility, data on EM usage in 2011
was collected according to official documents. A semi-
structured questionnaire was then completed by the
chief pharmacy manager to determine the reform’s im-
pact on each facility. Meanwhile, semi-structured ques-
tionnaires were distributed to doctors. At least 16
doctors were chosen in four randomly selected medical
departments in each upper-level hospital, and 10 doctors
were chosen in each primary hospital. These doctors
were asked questions about EM prescription. We also
chose large medicine manufacturers (n = 17) and distri-
bution companies (n = 17) in Guangdong Province for
the investigation. Chief executives were requested to
complete the semi-structured questionnaires. The ques-
tionnaire included questions about their general circum-
stances, their suggestions and their concerns regarding
the current reform.Analysis method
All the data collected were carefully entered into a
spreadsheet created in Excel 2010 (Microsoft, USA). The
data were then transferred to SPSS (version 18.0) for
statistical analysis. A group comparison was performed
using the Mann–Whitney U test or the chi-square test.
A Spearman’s correlation test was employed to deter-
mine the relationship between the ratio of EMs in each
prescription and prescription drug costs. The level of
significance was set at P ≤ 0.05. The data in this paper
reflect median values (25th–75th interquartile range).
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Prescription analysis
At the deadline, 25 hospitals had fully reported their pre-
scription analyses of the four diseases, and four hospitals
had partially reported their records. A total of 10,117 pre-
scription records were reported, and 176 of these were
rejected because of missing information or input errors.
Ultimately, 9,941 (98.2%) prescriptions were included in
the analysis.
Rational use of medicines
The WHO defines the rational use of medicines as oc-
curring when “patients receive medications appropriate
to their clinical needs, in doses that meet their own indi-
vidual requirements, for an adequate period of time, and
at the lowest cost to them and their community.” The ir-
rational use of medicines refers to medical use without
following these criteria. We identified the following
common types of irrational medicine use: drug use with-
out indicators, inappropriate drug selection, inappropriate
dosage or usage, and inappropriate drug combination.
The percentage of non-priority use of EMs ranged from
8.1% to 10.7% (Table 1) in upper-level hospitals. Non-
priority use of EMs significantly increased the prescription
drug costs of treating hypertension, gout and bacterial in-
fections compared with the rational use of medicines.
Other types of irrational medicine use were found more
frequently for bacterial infections (7.4%) than for hyper-
tension (1.6%), diabetes (1.3%) and gout (1.7%).
Prescription pattern in upper-level hospitals
The prescription pattern in Table 2 shows that tertiary
hospitals prescribed fewer EMs than secondary hospitals
and with higher median prescription drug costs. The
total number of drugs showed no significant difference
with respect to prescription of medicines for hyperten-
sion, diabetes and gout, but the number was lower for
prescriptions for bacterial infections in tertiary hospitalsTable 1 Rational drug use in treating hypertension, diabetes,










Bacterial infections 100.5 89.1*
(2571) (64.0-151.2) (52.2-153
Rx = prescription; EMs = essential medicines.
On June 1, 2012, at the beginning of the survey, the conversion rate was RMB 6.33
*p < 0.05 and **p < 0.01 compared with the non-priority use of EMs.(mean ± SD: 3.51 ± 1.44 for secondary and 2.92 ± 1.53 for
tertiary hospitals). The Spearman’s correlation coefficient
for the ratio of EMs to prescription drug costs was −0.344
for hypertension, −0.200 for diabetes, −0.282 for bacter-
ial infections, and −0.477 for gout in upper-level hospi-
tals. These correlations were significant but not strong
(p < 0.001).
Zero mark-up policy in secondary hospitals
In the secondary hospitals involved in the prescription
analysis, three had adopted the zero mark-up policy
(Table 3). The results indicated that the zero mark-up
policy decreased the total medicine costs and EM pre-
scription costs of treating most diseases. The hospitals
that had adopted the zero mark-up policy prescribed
fewer drugs for hypertension (mean ± SD: 2.01 ± 1.18 for
those with zero mark-up and 2.36 ± 1.43 for those with-
out zero mark-up) and bacterial infections (mean ± SD:
3.17 ± 1.37 for those with zero mark-up and 3.62 ± 1.44
for those without zero mark-up) but prescribed more
drugs for gout (mean ± SD: 3.39 ± 1.37 for those with
zero mark-up and 2.81 ± 1.31 for those without zero
mark-up).
Surveys in health care facilities
The EM usage for 2011 is shown in Table 4 for 63 pri-
mary, 16 secondary, and 19 tertiary hospitals. The stored
types of EMs constituted 97.5% (90.0%, 100.0%), 37.5%
(30.0%, 40.0%), and 29.9% (28.5%, 35.3%) of the total
types of drugs stored by primary, secondary, and tertiary
hospitals, respectively. Furthermore, 92% of primary hos-
pitals, 25% of secondary hospitals, and 5% of tertiary
hospitals had adopted the zero mark-up policy.
After the reform, the change in the number of patient
visits was significantly associated with hospital levels, χ2
(2, N = 98) = 30.16, p < 0.001, Cramer’s V = 0.56. As re-
ported by the person in change in each hospital, the num-















to USD 1.00. Data are shown as medians (25th–75th interquartile range).
Table 2 A comparison of secondary and tertiary hospitals regarding the availability, number and cost of essential
medicines
Hospital (n Rx) EMs/Rx number (%) EM number Total drug number EMs/Rx cost (%) EM cost (RMB) Total Rx cost (RMB)
Hypertension (r = −0.344)#
Secondary 80 2 3 73 44.7 98.1
(1058) (50–100) (1–3) (2–4) (32–100) (15.9-92.7) (42.9-178.22)
Tertiary 50** 1** 3 34** 51.24 184.9**
(1387) (25–75) (1–2) (2–4) (4–82) (7.1-133.5) (98.6-329.2)
Diabetes (r = −0.200)
Secondary 80 2 3 91 74.9 128.8
(1164) (50–100) (1–3) (2–4) (41–100) (24.6-167.2) (63.9-245.3)
Tertiary 50** 1** 2 53** 100.1* 231.1**
(1686) (25–100) (1–2) (1–4) (8–100) (14.9-212.4) (133.9-384.9)
Gout (r = −0.477)
Secondary 75 2 3 77 17.7 35.6
(956) (50–100) (1–3) (2–4) (21–100) (5.2-30.2) (20.9-68.3)
Tertiary 40** 1** 3 5** 4.0** 99.2**
(1119) (0–60) (0–2) (2–4) (0–24) (0–19.9) (50.3-182.0)
Bacterial infections (r = −0.282)
Secondary 60 2 3 47 31.2 85.7
(1196) (40–80) (1–3) (2–5) (13–92) (9.8-66.9) (51.85-131.4)
Tertiary 50** 1** 3** 30** 22.4** 99.8**
(1375) (20–80) (1–2) (2–4) (1–97) (0.8-62.3) (55.9-180.1)
Rx = prescription; EMs = essential medicines.#Spearman correlation coefficient between the ratio of EMs and prescription medicine costs in upper-level hospitals
(p < 0.001).
On June 1, 2012, at the beginning of the survey, the conversion rate was RMB 6.33 to USD 1.00. Data are shown as medians (25th–75th interquartile range).
*p < 0.05 and **p < 0.01 compared with secondary hospitals.
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primary hospitals and 22.9% of upper-level hospitals, and
remained unchanged in 23.8% of primary and 74.3% of
upper-level hospitals after the reform. Moreover, 47.6% of
primary hospitals believed that government subsidies were
not sufficient to compensate for the losses from zero
mark-up, 15.9% believed that the subsidies were sufficient,
and 36.5% believed that the subsidies compensated for
slightly less than the loss. The questionnaire results
showed that some local health authorities created a re-
gional EM list.
Surveys of doctors
A total of 1,600 questionnaires were distributed to doc-
tors in these hospitals, and 1,509 valid questionnaires
were obtained (650 from primary hospitals and 859 from
upper-level hospitals), yielding a valid response rate of
94.3%. Only 8.6% of doctors in primary hospitals and
17.7% in upper-level hospitals believed that the EMs
fully met clinical needs. Furthermore, many doctors in
primary hospitals reported that insufficient types of EM
hindered their treatment. We also investigated the rea-
sons for not prescribing EMs in upper-level hospitals,and the results indicate the following reasons: 48.8% for
“I do not trust the quality and efficacy of EMs”; 35.5%
for “The drugs on the list are not enough for clinical
use”; 10.2% for “The patients refuse to use EMs”; and
5.5% “I do not know which drugs are the EMs”.
Surveys of manufacturers and distribution companies
The annual output value was 393 (228, 1488) million
Yuan for these manufacturers, and 64 (43, 96) types of
drugs were produced, in which EMs accounted for 40%
(20%, 60%). There were 4 (1, 23) types of EMs for which
production had been halted at the time of the survey. In
distribution companies, the four factors cited as most in-
fluential to distribution were delayed payment (35%),
low demand (12%), high distribution costs (23%), and
cessation of production by manufacturers (29%). The
average period of payment settlement was 64% between
3 and 6 months, 29% at more than 6 month, and only
6% within the contracted period of 2 months.
Discussion
This investigation revealed the EM prescription pattern
and the current state of the EM system in Guangdong
Table 3 The comparison of the zero mark-up policy in secondary hospitals
Zero mark-up EMs/Rx number (%) EM number Total drug number EMs/Rx cost (%) EM cost (RMB) Total Rx cost (RMB)
Hypertension
Adopted 100 2 2 100 30.2 65.5
(299) (60–100) (1–3) (2–3) (39–100) (14.0-83.3) (17.6-140.3)
Not adopted 75** 2** 3** 64** 51.3** 102.1**
(759) (50–100) (1–3) (2–5) (26–100) (20.0-97.6) (54.1-200.8)
Diabetes
Adopted 67 2 3 56 24.5 100.5
(304) (50–100) (1–3) (2–3) (13–100) (9.6-105.3) (39.9-189.3)
Not adopted 100** 2 3 99** 85.4** 136.0**
(860) (50–100) (1–3) (1–4) (52–100) (38.7-180.9) (69.5-261.1)
Gout
Adopted 75 3 3 66 11.6 30.5
(232) (50–100) (1–4) (3–5) (14–100) (4.3-25.3) (13.8-82.1)
Not adopted 75 2** 3** 84 21.0** 35.9
(724) (50–100) (1–4) (2–4) (21–100) (5.2-31.5) (21.4-62.1)
Bacterial infections
Adopted 60 2 3 55 32.6 76.0
(297) (30–100) (1–3) (2–4) (8–100) (3.6-71.5) (42.0-117.9)
Not adopted 60 2** 3** 43 31.0 88.6**
(899) (40–80) (1–3) (3–5) (14–88) (12.2-65.3) (53.2-139.4)
Rx = prescription; EMs = essential medicines.
On June 1, 2012, at the beginning of the survey, the conversion rate was RMB 6.33 to USD 1.00. Data are shown as medians (25th–75th interquartile range).
**p < 0.01 compared with the zero mark-up group.
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costs in upper-level hospitals include ensuring priority
EM use and adopting the zero mark-up policy. However,
it is unrealistic to promote the zero mark-up policy in
upper-level hospitals because of limited government
budgets. Improving the priority use of essential drugs is
a more realistic approach. Currently, the government en-
courages hospitals to recruit enough clinical pharmacists
to monitor prescriptions because clinical pharmacists
are thought to positively influence the appropriate use of
prescription drugs [13].
Although the priority use of EMs is encouraged, their
use is not mandatory in upper-level hospitals. We foundTable 4 Essential medicine usage in hospitals in Guangdong
Hospital (n) EMs types EMs/Total types (%) EMs/Total sales (%)
Primary 305 97.5 95.7
(63) (239–425) (90.0-100.0) (84.8-100.0)
Secondary 345 37.5 23.2
(16) (298–379) (30.0-40.0) (16.9-25.6)
Tertiary 377 29.9 15.0
(19) (345–422) (28.5-35.3) (12.1-21.0)
EMs = essential medicines. Data are shown as medians (25th–75th interquartile rangthat the ratio of non-priority use of EMs was not high, but
the use of non-priority EMs significantly increased pre-
scription medicine costs. Except for non-priority EM use,
the most common inappropriate use was to treat bacterial
infections. In 2009, the Ministry of Health published a
strict policy to strengthen the management of antibiotics,
but inappropriate antibiotic use still accounted for a large
proportion of irrational drug use. The misuse of antibi-
otics poses considerable risks for drug resistance, toxicity,
and allergic reactions. Multi-faceted strategies are required
to improve rational antibiotic use, including education, re-
placement of economic incentives, promotion of best
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hospitals and had higher prescription drug costs, which
might be partly explained by the fact that the tertiary hos-
pitals typically provided treatment for costly and complex
diseases [15]. Except for the treatment of bacterial in-
fections, the average number of drugs per prescription
showed no significant difference between secondary and
tertiary hospitals. A median of three drugs were used per
prescription, which was markedly higher than the WHO
recommended values of 1.3 to 2.0 [7]. The reason for this
discrepancy may be attributable to symptomatic treatment
and inappropriate practice patterns by doctors.
Consistent with previous studies conducted in primary
hospitals [5], the secondary hospitals that had adopted
the zero mark-up policy also decreased total prescription
costs. However, we did not find that implementing the
zero mark-up policy would necessarily decrease the pre-
scription drug numbers or increase the use of EMs.
Other researchers have found that the number of drugs
prescribed was reduced but that the number of inject-
able drugs increased in primary hospitals [5,16]. One
aim of the zero mark-up policy is to improve the rational
use of medicines by eliminating economic incentives for
health care institutions, but current studies indicate that
this objective has not been reached [17,18].
Improvements in primary care are critical because they
not only can decrease health care expenditures per capita
but also can boost health conditions and health care out-
comes [19,20]. However, this survey found that the num-
ber of patient visits to most primary hospitals decreased.
Other studies have reported the same phenomenon: be-
cause the EMs did not fully meet clinical needs, some pa-
tients were transferred to upper-level hospitals [21]. The
sufficiency of the EM supply was also a concern for doc-
tors in primary hospitals in this survey. This phenomenon
has attracted government attention, and drug numbers in-
creased in a new national EM list published in September
2012 [22]. However, it remains unresolved whether the
new list can overcome the effects of prescription restric-
tions in primary hospitals. Meanwhile, the zero markup
policy made grassroots hospitals rely more heavily on fi-
nancial subsidies from local governments [5,23]. However,
it was reported that local governments may not take suffi-
cient responsibility for the scientific design and funding of
the EM policy, which could threaten the viability of the
zero mark-up policy [6].
It is critical to maintain a balance between drug price
and quality in the bidding system. Overweighting the price
in the bidding system would result in the production of
low-quality EMs or make manufacturers reluctant to pro-
duce profitless EMs [21]. Currently, the availability of
lowest-priced generic drugs in China has become a sub-
stantial problem [24]. To promote normal production and
supply of low-cost drugs, the “Guangdong ProvincialLow-cost Drug List of EMs” has been created. The list of
drugs will only follow the quality standards [25]. The sur-
vey showed that payments from hospitals were always de-
layed. To improve timely payment settlement, a centralized
settlement system will be established by the Guangdong
Pharmaceutical Exchange that will automatically settle ac-
counts according to a “Settlement Services Agreement”
when the settlement period is longer than 60 days [26].
The present research has several limitations. The find-
ings in Guangdong Province may not be regarded as
representative of all of China. The irrational use of medi-
cines was manually assessed, which might indicate that
there is potential bias. In addition, only a few secondary
hospitals had adopted the zero mark-up policy, which
limited the sample size.
Conclusions
Two effective ways to reduce prescription drug costs in
upper-level hospitals are to ensure priority EM use and to
adopt the zero mark-up policy. Further work should be fo-
cused on improving EM use in upper-level hospitals. For
primary hospitals, a more rational financial subsidy policy
should be offered to ensure the viability of zero mark-up
policies. Doctors should receive guidance regarding ra-
tional prescribing practices, particularly in treating bacter-
ial infections. For manufacturers, a scientific design in the
bidding system should be implemented to ensure a steady
supply of the lowest-priced generic drugs. For distribution
companies, timely settlement should be improved.
Competing interests
The authors declare that they have no competing interests. This study was
supported by the Health Economics Association of Guangdong Province
(Project number 20122304). The sponsor had no influence on the study
design; collection, analysis, or interpretation of the data; or the writing of the
manuscript.
Authors’ contributions
YJL led the study. He designed the study, led the data collection, analysis,
and interpretation. WYZ and YRL analyzed the data. WYZ wrote the draft of
the manuscript. XQL, RZL, and WGZ contributed to the study design, data
collection. All authors read and approved the final manuscript.
Acknowledgements
We would like to thank the regional directors, clinical pharmacists and
respondents for their contribution to the current work.
Author details
1Department of Pharmacy, Zhongshan Hospital of Sun Yat-sen University,
Zhongshan 528403, China. 2School of Pharmaceutical Sciences, Sun Yat-sen
University, Guangzhou 510006, China.
Received: 19 May 2014 Accepted: 4 March 2015
References
1. Barber SL, Huang B, Santoso B, Laing R, Paris V, Wu C. The reform of the
essential medicines system in China: a comprehensive approach to
universal coverage. J Global Health. 2013;3(1):10303.
2. Chen Z. Launch of the health-care reform plan in China. Lancet. 2009;373
(9672):1322–4.
Zhang et al. BMC Health Services Research  (2015) 15:98 Page 7 of 73. Reidenberg MM. Can the selection and use of essential medicines decrease
inappropriate drug use? Clin Pharmacol Ther. 2009;85(6):581–3.
4. Younis MZ, Hamidi S, Forgione DA, Hartmann M. Rational use effects of
implementing an essential medicines list in West Bank, Palestinian
Territories. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):243–50.
5. Yang L, Cui Y, Guo S, Brant P, Li B, Hipgrave D. Evaluation, in three
provinces, of the introduction and impact of China’s National Essential
Medicines Scheme. Bull World Health Organ. 2013;91(3):184–94.
6. Xiao Y, Zhao K, Bishai DM, Peters DH. Essential drugs policy in three rural
counties in China: what does a complexity lens add? Soc Sci Med.
2013;93:220–8.
7. Wang H, Li N, Zhu H, Xu S, Lu H, Feng Z. Prescription pattern and its
influencing factors in Chinese county hospitals: a retrospective cross-
sectional study. PLoS One. 2013;8(5):e63225.
8. Dong L, Yan H, Wang D. Drug prescribing indicators in village health clinics
across 10 provinces of Western China. Fam Pract. 2011;28(1):63–7.
9. Yang H, Dib HH, Zhu M, Qi G, Zhang X. Prices, availability and affordability
of essential medicines in rural areas of Hubei Province, China. Health Policy
Plan. 2010;25(3):219–29.
10. Wei J, Li Y, Zhu S, Chen Y, Xiao X. Investigation and analysis of status Quo
for the implementation of National Essential Drug System in primary health
care institutions in Hangzhou. China Pharmacy. 2012;23(36):3379–83.
11. Cai M, Lin C, Li Y, Luo X, Li Z. Investigation of the situation of drug use in
primary health care institutions of Shantou Chaonan District before and
after the implementation of National Essential Medicine System. China
Pharmacy. 2013;24(28):2605–7.
12. Han W, Qu W. Knowledge, attitudes and practices of primary doctors
in Yantai on National Essential Drug System. Chin Gen Pract. 2013;
16(4A):1103–4. 1107.
13. Penm J, Li Y, Zhai S, Hu Y, Chaar B, Moles R. The impact of clinical pharmacy
services in China on the quality use of medicines: a systematic review in
context of China’s current healthcare reform. Health Policy Plan. 2014;
29(7):849–72.
14. Reynolds L, McKee M. Factors influencing antibiotic prescribing in China: an
exploratory analysis. Health Policy. 2009;90(1):32–6.
15. Chen W, Tang S, Sun J, Ross-Degnan D, Wagner AK. Availability and use of
essential medicines in China: manufacturing, supply, and prescribing in
Shandong and Gansu provinces. BMC Health Serv Res. 2010;10:211.
16. Yip WC-M, Hsiao WC, Chen W, Hu S, Ma J, Maynard A. Early appraisal of
China’s huge and complex health-care reforms. Lancet. 2012;379(9818):833–42.
17. Chen M, Wang L, Chen W, Zhang L, Jiang H, Mao W. Does economic
incentive matter for rational use of medicine? China’s experience from the
Essential Medicines Program. Pharmacoeconomics. 2014;32(3):245–55.
18. Yang L, Liu C, Ferrier JA, Zhou W, Zhang X. The impact of the National
Essential Medicines Policy on prescribing behaviours in primary care
facilities in Hubei province of China. Health Policy Plan. 2013;28(7):750–60.
19. Macinko J, Starfield B, Shi L. The contribution of primary care systems to
health outcomes within Organization for Economic Cooperation and
Development (OECD) countries, 1970–1998. Health Serv Res. 2003;38(3):831–65.
20. Kruk ME, Porignon D, Rockers PC, Van Lerberghe W. The contribution of
primary care to health and health systems in low- and middle-income
countries: a critical review of major primary care initiatives. Soc Sci Med.
2010;70(6):904–11.
21. Hu S. Essential medicine policy in China: pros and cons. J Med Econ.
2013;16(2):289–94.
22. National Health and Family Planning Commission of China. Answers to the
questions about National Essential Medicine List related policies. [http://
www.moh.gov.cn/mohywzc/s3582/201303/57a7b9ead4074247b9f9bf
31a137689b.shtml]
23. Hipgrave D, Guo S, Mu Y, Guo Y, Yan F, Scherpbier R, et al. Chinese-style
decentralization and health system reform. PLoS Med. 2012;9(11):e1001337.
24. Fang Y, Wagner AK, Yang S, Jiang M, Zhang F, Ross-Degnan D. Access to
affordable medicines after health reform: evidence from two cross-sectional
surveys in Shaanxi Province, western China. Lancet Global Health.
2013;1(4):e227–37.
25. Price Bureau of Guangdong Province. Guangdong Province low-cost drug
list of essential medicine. [http://www.gdpi.gov.cn/tztg/419360.jhtml]
26. The General Office of Guangdong Province. Reinforce and improve the
basic drug system and the new system of grass-roots Implementation Plan.
[http://zwgk.gd.gov.cn/006939748/201309/t20130909_404674.html]Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
